Measurement of the charged pion mass using X-ray spectroscopy of exotic atoms

The $5g-4f$ transitions in pionic nitrogen and muonic oxygen were measured simultaneously by using a gaseous nitrogen-oxygen mixture at 1.4\,bar. Due to the precise knowledge of the muon mass the muonic line provides the energy calibration for the pionic transition. A value of (139.57077\,$\pm$\,0.00018)\,MeV/c$^{2}$ ($\pm$\,1.3ppm) is derived for the mass of the negatively charged pion, which is 4.2ppm larger than the present world average

Characterization of a CCD array for Bragg spectroscopy

The average pixel distance as well as the relative orientation of an array of 6 CCD detectors have been measured with accuracies of about 0.5 nm and 50 $\mu$rad, respectively. Such a precision satisfies the needs of modern crystal spectroscopy experiments in the field of exotic atoms and highly charged ions. Two different measurements have been performed by illuminating masks in front of the detector array by remote sources of radiation. In one case, an aluminum mask was irradiated with X-rays and in a second attempt, a nanometric quartz wafer was illuminated by a light bulb. Both methods gave consistent results with a smaller error for the optical method. In addition, the thermal expansion of the CCD detectors was characterized between -105 C and -40 C.Comment: Submitted to Review of Scientific Instrument

X-Ray Transitions from Antiprotonic Noble Gases

The onset of antiprotonic X-ray transitions at high principal quantum numbers and the occurence of electronic X-rays in antiprotonic argon, krypton, and xenon has been analyzed with the help of Multiconfiguration Dirac-Fock calculations. The shell-by-shell ionisation by Auger electron emission, characterised by appearance and disappearance of X-ray lines, is followed through the antiprotonic cascade by considering transition and binding energies of both the antiproton and the remaining electrons. Electronic lines could be attributed partly to specific states of the antiprotonic atom de-excitation.Comment: 16 pages, 13 figure

Hadronic shift in pionic hydrogen

The hadronic shift in pionic hydrogen has been redetermined to be $\epsilon_{1s}=7.086\,\pm\,0.007(stat)\,\pm\,0.006(sys)$\,eV by X-ray spectroscopy of ground state transitions applying various energy calibration schemes. The experiment was performed at the high-intensity low-energy pion beam of the Paul Scherrer Institut by using the cyclotron trap and an ultimate-resolution Bragg spectrometer with bent crystals.Comment: 10 pages, 6 figure

Highly charged ion X-rays from Electron-Cyclotron Resonance Ion Sources

Radiation from the highly-charged ions contained in the plasma of Electron-Cyclotron Resonance Ion Sources constitutes a very bright source of X-rays. Because the ions have a relatively low kinetic energy ($\approx 1$ eV) transitions can be very narrow, containing only small Doppler broadening. We describe preliminary accurate measurements of two and three-electron ions with Z=16--18. We show how these measurement can test sensitively many-body relativistic calculations or can be used as X-ray standards for precise measurements of X-ray transitions in exotic atoms

Line shape of the muH(3p - 1s) hyperfine transitions

The (3p - 1s) X-ray transition to the muonic hydrogen ground state was measured with a high resolution crystal spectrometer. A Doppler effect broadening of the X-ray line was established which could be attributed to different Coulomb de-excitation steps preceding the measured transition. The assumption of a statistical population of the hyperfine levels of the muonic hydrogen ground state was directly confirmed by the experiment and measured values for the hyperfine splitting can be reported. The results allow a decisive test of advanced cascade model calculations and establish a method to extract fundamental strong-interaction parameters from pionic hydrogen experiments.Comment: Submitted to Physical Review Letter

Determination of pulsation periods and other parameters of 2875 stars classified as MIRA in the All Sky Automated Survey (ASAS)

We have developed an interactive PYTHON code and derived crucial ephemeris data of 99.4% of all stars classified as 'Mira' in the ASAS data base, referring to pulsation periods, mean maximum magnitudes and, whenever possible, the amplitudes among others. We present a statistical comparison between our results and those given by the AAVSO International Variable Star Index (VSX), as well as those determined with the machine learning automatic procedure of Richards et al. 2012. Our periods are in good agreement with those of the VSX in more than 95% of the stars. However, when comparing our periods with those of Richards et al, the coincidence rate is only 76% and most of the remaining cases refer to aliases. We conclude that automatic codes require still more refinements in order to provide reliable period values. Period distributions of the target stars show three local maxima around 215, 275 and 330 d, apparently of universal validity, their relative strength seems to depend on galactic longitude. Our visual amplitude distribution turns out to be bimodal, however 1/3 of the targets have rather small amplitudes (A $<$ 2.5$^{m}$) and could refer to semi-regular variables (SR). We estimate that about 20% of our targets belong to the SR class. We also provide a list of 63 candidates for period variations and a sample of 35 multiperiodic stars which seem to confirm the universal validity of typical sequences in the double period and in the Petersen diagramsComment: 14 pages, 14 figures, and 8 tables. Accepted to The Astrophysical Journal Supplement Series, September 201

The TAO kinase KIN-18 regulates contractility and establishment of polarity in the C. elegans embryo

AbstractCell polarity is crucial for many aspects of cell and developmental biology. Cytoskeleton remodeling plays an essential role in the establishment of cell polarity. In the Caenorhabditis elegans one-cell embryo, while the actomyosin cytoskeleton is required for asymmetric localization of the PAR proteins, anterior PAR proteins exert a feedback regulation on contractility. Here we identify the TAO kinase KIN-18 as a regulator of cortical contractility in the early embryo. KIN-18 negatively regulates cortical contractions in a RHO-1 dependent manner and regulates RHO-1 cortical localization. KIN-18 contributes to polarity establishment by regulating the position of the boundary between anterior and posterior PAR proteins. Although KIN-18 is involved in polarity establishment, depletion of KIN-18 restores contractions in a par-3 mutant indicating that kin-18 is epistatic to par-3. We suggest a model in which KIN-18 provides a link between the cytoskeleton remodeling and polarity machineries, uncovering a role for TAO kinases in the regulation of cell polarity

High Resolution He-like Argon And Sulfur Spectra From The PSI ECRIT

We present new results on the X-ray spectroscopy of multicharged argon, sulfur and chlorine obtained with the Electron Cyclotron Resonance Ion Trap (ECRIT) in operation at the Paul Scherrer Institut (Villigen, Switzerland). We used a Johann-type Bragg spectrometer with a spherically-bent crystal, with an energy resolution of about 0.4 eV. The ECRIT itself is of a hybrid type, with a superconducting split coil magnet, special iron inserts which provides the mirror field, and a permanent magnetic hexapole. The high frequency was provided by a 6.4 GHz microwave emitter. We obtained high intensity X-ray spectra of multicharged F-like to He-like argon, sulfur and chlorine with one 1s hole. In particular, we observed the 1s2s^{3}S_1 \to 1s^2^{1}S_0 M1 and 1s2p^{3}P_2 \to 1s^2^{1}S_0 M2 transitions in He-like argon, sulfur and chlorine with unprecedented statistics and resolution. The energies of the observed lines are being determined with good accuracy using the He-like M1 line as a reference

Suivi thérapeutique de l'imatinib

* Le monitoring (suivi) joue un rôle important pour un traitement et son évaluation - pour autant qu'il se base sur la mesure de marqueurs cliniques adéquats ou de substituts validés. * Pour ce qui est du traitement d'imatinib, le «therapeutic drug monitoring» (TDM) semble être une option utile pour le contrôle du traitement de la LMC. Il utilise la concentration plasmatique de ce médicament comme marqueur. * Les concentrations plasmatiques d'imatinib varient considérablement d'un patient à l'autre sous un même schéma posologique, en raison de la variabilité interindividuelle de sa pharmacocinétique. Il a été démontré que l'exposition plasmatique était en corrélation avec le résultat clinique des patients LMC - aussi bien pour la réponse au traitement que pour le profil d'effets indésirables. * Il n'est pas encore établi si le TDM de l'imatinib doit être utilisé que dans le cas de problèmes cliniques ou si les patients LMC peuvent déjà profiter d'un contrôle préventif systématique «de routine» - de manière à garder la concentration plasmatique dans des marges thérapeutiques. Cela est toujours plus recommandé ces derniers temps. * Pour répondre à cette question, une étude suisse prospective, randomisée et contrôlée recrute des patients LMC traités par imatinib depuis moins de 5 ans et propose en outre le TDM pour tous les patients en cas de problèmes cliniques. - * Monitoring spielt eine wichtige Rolle zur Therapieevaluierung und Behandlungsentscheidung - solange es auf der Basis der Messung von entsprechenden klinischen oder validierten Surrogat-Markern stattfindet. * Im Hinblick auf die Imatinib-Therapie scheint das «Therapeutische Drug-Monitoring» (TDM) ein nützlicher Ansatz zum Therapie-Monitoring der CML-Behandlung zu sein, welches die Plasmakonzentration des Arzneimittels als Marker zur Therapieüberwachung verwendet. * Imatinib-Plasmakonzentrationen variieren beträchtlich von Patient zu Patient unter dem gleichen Dosierungsschema, aufgrund der interindividuell unterschiedlichen Pharmakokinetik des Arzneimittels. Für die Plasmaexposition wurde gezeigt, dass sie mit dem klinischen Outcome von CML-Patienten korreliert - sowohl im Bezug auf das Therapieansprechen als auch auf das Nebenwirkungsprofil. * Es ist noch unklar, ob das TDM von Imatinib nur im Falle von klinischen Problemen Verwendung finden sollte oder ob CML-Patienten bereits von einem systematischen, präventiven «Routine»-Monitoring zur Therapieindividualisierung - zur Steuerung der Plasmakonzentration in einen therapeutischen Bereich - profitieren könnten, welches in letzter Zeit immer häufiger empfohlen wird. * Um diese Fragestellung zu beantworten, nimmt eine prospektive, randomisiert kontrollierte Schweizer Studie CML-Patienten auf, die seit weniger als 5 Jahren mit Imatinib behandelt werden, und bietet das TDM zudem für alle Patienten im Falle von klinischen Problemen an